NYXH Nyxoah

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023



Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Mont-Saint-Guibert, Belgium – March 8, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link:  . A live and archived webcast of the event will be available on the Company’s investor relations website at .

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit .

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

David DeMartino, Chief Strategy Officer





Attachment



EN
08/03/2023

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Reports Second Quarter Financial and Operating Results

Nyxoah Reports Second Quarter Financial and Operating Results REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent F...

August 18, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Sec...

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025 INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025La FDA approuve le système Genio® pour le marché américain ; la Société lance la commercialisation du produit Mont-Saint-Guibert, Belgique – 18 août 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) ...

August 18, 2025 1 EN
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
08/12/25 August 12, 2025 1 FR
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business U...

August 11, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre ...

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025  Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui certains résultats financiers préliminaires non audités pour le deuxième trimestre 2025 et d'autres informations su...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch